NCT05721950Active, not recruiting
A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)
A Real-World Study to Evaluate the Effectiveness and Safety of Brigatinib in First Line in Patients With ALK Positive Locally Advanced or Metastatic NSCLC in China: An Ambispective, Non-interventional, Observational, Multi-center Study.
Source: ClinicalTrials.gov · Last updated 18 Feb 2026
Brief summary (registry, in English)
The main aim of this study is to learn about the time between the start and stop of treatment with brigatinib in Chinese participants with non-small-cell lung cancer (NSCLC) and who have been positively diagnosed with having the anaplastic lymphoma kinase (ALK) gene. Other study aims are to learn about the progression of NSCLC and participants' response to treatment with brigatinib.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 154 (actual)
- First submitted
- 1 Feb 2023
- Start date
- Jan 2024
- Primary completion date
- Mar 2028
- Lead sponsor
- Takeda
- Diseases
- Lung cancer
- NCT number
- NCT05721950
What you commit to
- Study type: Observational
- Participants enrolled: 154
- From Jan 2024 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously received any other TKIs, including ALK-targeted TKIs.
- Previously received more than 1 regimen of systemic anticancer therapy for locally advanced or metastatic disease.
Other illness
- Participants have been diagnosed as malignancies (excluding completely resected basal cell carcinoma, bladder carcinoma in situ, cervical carcinoma in situ) in addition to NSCLC within the past 5 years.
Other
- Participants participated in NSCLC-related interventional clinical trials after locally advanced or metastatic NSCLC diagnosis and during brigatinib treatment.
Who the study is looking for
- Age ≥ 18 years.
- Participant with histologically/cytologically confirmed locally advanced or metastatic NSCLC.
- Participants with ALK gene rearrangement confirmed by local hospital medical records.
- Participants who received brigatinib since September 1, 2022 as first line treatment confirmed by medical records.
- Participants who have at least one medical record after the start of brigatinib treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Oncology, Shanghai pulmonary hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.